Effect of patient's life expectancy on the cost-effectiveness of treatment for ocular hypertension

Archives of Ophthalmology

Volumn 128, Issue 5, 2010, Pages 613-618

  Kymes, Steven M ^a,b   Plotzke, Michael R ^c   Kass, Michael A ^b   Boland, Michael V ^d   Gordon, Mae O ^a,b  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ABT ASSOCIATES   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT;

ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; INTRAOCULAR HYPERTENSION; LIFE EXPECTANCY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; GLAUCOMA, OPEN-ANGLE; HEALTH CARE COSTS; HUMANS; LIFE EXPECTANCY; MARKOV CHAINS; MIDDLE AGED; MODELS, STATISTICAL; OCULAR HYPERTENSION; PATIENTS; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS;

EID: 77952231148     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2010.83     Document Type: Article

References (24)

1. Parrish RK II, Gedde SJ, Scott IU, et al. Visual function and quality of life among patients with glaucoma. Arch Ophthalmol. 1997;115(11):1447-1455. (Pubitemid 28055876)
2. Lee PP, Walt JG, Doyle JJ, et al. A multicenter retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol. 2006;124(1):12-19.
3. Kobelt-Nguyen G, Gerdtham UG, Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma. 1998;7(2):95-104. (Pubitemid 28196096)
4. Friedman DS, Wolfs RC, O'Colmain BJ, et al; Eye Diseases Prevalence Research Group. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122(4):532-538.
5. Kymes SM, Kass MA, Anderson DR, Miller JP, Gordon MO; Ocular Hypertension Treatment Study Group. Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2006;141(6):997-1008.
6. Russell LB, Sisk JE. Modeling age differences in cost-effectiveness analysis: a review of the literature. Int J Technol Assess Health Care. 2000;16(4):1158-1167.
7. Kanis JA, Dawson A, Oden A, Johnell O, de Laet C, Jonsson B. Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int. 2001;12(5):356-361. (Pubitemid 32606458)
8. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713.
9. Hattenhauer MG, Johnson DH, Ing HH, et al. The probability of blindness from open-angle glaucoma. Ophthalmology. 1998;105(11):2099-2104.
10. Anderson RN. A method for constructing complete annual US life tables. Vital Health Stat 2. 2000;(129):1-28.
11. Lairson DR, Begley CE, Reynolds TF, Wilhelmus KR. Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis. Arch Ophthalmol. 2003; 121(1):108-112. (Pubitemid 36401775)
12. Busbee BG, Brown MM, Brown GC, Sharma S. Cost-utility analysis of cataract surgery in the second eye. Ophthalmology. 2003;110(12):2310-2317. (Pubitemid 37485160)
13. Meads C, Hyde C. What is the cost of blindness? Br J Ophthalmol. 2003;87(10): 1201-1204. (Pubitemid 37193905)
14. Jampel HD, Schwartz A, Pollack I, Abrams D, Weiss H, Miller R. Glaucoma patients' assessment of their visual function and quality of life. J Glaucoma. 2002; 11(2):154-163. (Pubitemid 34298597)
15. Lee BS, Kymes SM, Nease RF Jr, Sumner W, Siegfried CJ, Gordon MO. The impact of anchor point on utilities for 5 common ophthalmic diseases. Ophthalmology. 2008;115(5):898-903.e4.
16. Brown MM, Brown GC, Sharma S, Kistler J, Brown H. Utility values associated with blindness in an adult population. Br J Ophthalmol. 2001;85(3):327-331. (Pubitemid 32250764)
17. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397-409. (Pubitemid 28140699)
18. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. Oxford, England: Oxford University Press; 1997:305.
19. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996:425.
20. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase with the rate of inflation? Arch Intern Med. 2003;163(14): 1637-1641.
21. Gillick MR. Medicare coverage for technological innovations: time for new criteria? N Engl J Med. 2004;350(21):2199-2203. (Pubitemid 38659502)
22. Arias E. United States life tables, 2003. Natl Vital Stat Rep. 2006;54(14):1-40.
23. Klein BEK, Klein R, Linton KLP. Intraocular pressure in an American community: the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci. 1992;33(7):2224-2228.
24. Brock DW. Ethical issues in the use of cost effectiveness analysis for the prioritisation of health care resources. In: Anand S, Peter F, Sen A, eds. Public Health, Ethics, and Equity. Oxford, England: Oxford University Press; 2004.